Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases

Zacks12-17

Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug Vabysmo (faricimab). The regulatory body approved Vabysmo PFS for use in the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492647708?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YaeP6YMQifV47czKTk1orA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55","is_english":true,"pubTime":"2024-12-17 02:40","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492647708","market":"us","top_or_hot":-1,"title":"Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases","media":"Zacks","content":"<div>\n<p>Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug Vabysmo (faricimab).\nThe regulatory body approved Vabysmo PFS for use in the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-gets-approval-vabysmo-pfs-184000806.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 02:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-gets-approval-vabysmo-pfs-184000806.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug Vabysmo (faricimab).\nThe regulatory body approved Vabysmo PFS for use in the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-gets-approval-vabysmo-pfs-184000806.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1868837136.USD","symbol_name":"CT (LUX) I AMERICAN \"8\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/roche-gets-approval-vabysmo-pfs-184000806.html","article_id":"2492647708","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YaeP6YMQifV47czKTk1orA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492647708","pubTimestamp":1734374400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe  of the ophthalmology drug Vabysmo .The regulatory body approved Vabysmo PFS for use in the treatment of neovascular or ‘wet’ age-related macular degeneration , diabetic macular edema  and macular edema following retinal vein occlusion .In the past three months, shares of Roche have lost 9.1% compared with the industry’s 14.3% decline.The approval of the Vabysmo prefilled syringe in the EU offers a convenient way to administer this leading ophthalmology treatment for people with three of the most common causes of vision loss.These three conditions — nAMD , DME and RVO — affect more than 9 million people in the EU.The PFS delivers the same drug as the currently available 6.0 mg Vabysmo vials in an alternative, ready-to-use format.Per Roche, Vabysmo PFS will be the EU’s first and only prefilled syringe containing a bispecific antibody to treat retinal conditions that can cause blindness.Over the pas","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","REGN":"再生元制药公司","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","PFS":"Provident Financial Services Inc","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BMY":"施贵宝","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","BK4139":"生物科技","03165":"华夏欧优股对冲","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4211":"区域性银行","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","GILD":"吉利德科学","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","BK4559":"巴菲特持仓","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4550":"红杉资本持仓","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","RHHBY":"罗氏控股","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"罗氏Vabysmo PFS在欧盟获得治疗三种视网膜疾病的批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":1,"REGN":1,"PFS":1,"GILD":1,"BMY":0.9,"03165":0.6},"content_text":"Roche RHHBY announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug Vabysmo (faricimab).\nThe regulatory body approved Vabysmo PFS for use in the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).\nIn the past three months, shares of Roche have lost 9.1% compared with the industry’s 14.3% decline.\nImage Source: Zacks Investment Research\nMore on RHHBY’s Vabsymo PFS\nThe approval of the Vabysmo prefilled syringe in the EU offers a convenient way to administer this leading ophthalmology treatment for people with three of the most common causes of vision loss.\nThese three conditions —  nAMD , DME  and RVO — affect more than 9 million people in the EU.\nThe PFS delivers the same drug as the currently available 6.0 mg Vabysmo vials in an alternative, ready-to-use format.\nPer Roche, Vabysmo PFS will be the EU’s first and only prefilled syringe containing a bispecific antibody to treat retinal conditions that can cause blindness. \nThe FDA already approved the PFS for nAMD, DME and RVO in July 2024.\nVabysmo’s Growth Fuels RHHBY\nThe drug’s stellar performance has fueled Roche’s top-line growth since approval. Sales skyrocketed 79% to CHF 2.8 billion in the first nine months of 2024 on strong demand in all regions, mainly the United States.\nThe PFS approval should further drive growth.\nSales of Regeneron’s REGN blockbuster ophthalmology drug Eylea have been under pressure due to competition from Vabysmo. \nTo counter the decline in Eylea sales, Regeneron developed a higher dose of Eylea HD. Regeneron plans to strengthen the Eylea HD product profile through the anticipated launch of its differentiated PFS by mid-2025.\nApproval of new drugs and label expansion of the existing ones should bode well for Roche. Drugs like Vabysmo, Ocrevus, Hemlibra and Polivy fuel Roche’s top line as the company looks to fill up the dent in revenues caused by a decline in COVID-19-related sales. Competition from biosimilars for established drugs like Avastin, MabThera/Rituxan and Herceptin continues to hurt sales.\nRHHBY’s Zacks Rank & Stocks to Consider\nRoche currently carries a Zacks Rank #3 (Hold).\nA couple of better-ranked healthcare stocks are Gilead Sciences GILD and Bristol Myers BMY, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 60 days, estimates for Gilead Sciences’ 2024 earnings have risen from $3.77 to $4.36 per share. Estimates for 2025 earnings per share have increased from $7.27 to $7.55 in the same time frame. GILD’s shares have risen 11.4% in the past three months.\nGilead Sciences’ earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%.\nOver the past 60 days, estimates for Bristol Myers’ 2024 earnings have increased from 75 cents to 91 cents per share. Estimates for 2025 earnings per share have increased from $7.04 to $7.17 in the same time frame. BMY’s shares have gained 13.7% in the past three months.\nBristol Myers’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.54%. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nRegeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nBristol Myers Squibb Company (BMY) : Free Stock Analysis Report\nGilead Sciences, Inc. (GILD) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492647708"}